Shionogi & Co., Ltd.

Basic Information

Stock Code
4507
Industry
Pharmaceuticals
Category Detail
Biotechnology & Pharmaceuticals
Prefecture
Osaka Prefecture
Establishment Year
June 1919
Listing Year
May 1949
Official Website
https://www.shionogi.com/jp/ja/
TSE Information
TSE Information
Yahoo! Finance
Yahoo! Finance
Other Companies
Japan Tobacco Inc., Kyowa Kirin Co., Ltd., Takeda Pharmaceutical Co., Ltd., Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Ono Pharmaceutical Co., Ltd., Hisamitsu Pharmaceutical Co., Inc., Santen Pharmaceutical Co., Ltd., Torii Pharmaceutical Co., Ltd., Daiichi Sankyo Company, Limited, Otsuka Holdings Co., Ltd., FUJIFILM Holdings Corporation

Overview

Shionogi & Co., Ltd. is a major domestic pharmaceutical manufacturer founded in 1919, with infectious disease treatments as its mainstay, possessing high research and development capabilities and sales force, making it a key player in the industry.

Current Situation

Shionogi & Co., Ltd. achieved consolidated sales of approximately ¥438.3 billion and operating profit of approximately ¥156.6 billion in the fiscal year ending March 2025, maintaining steady business performance centered on infectious disease drugs and dyslipidemia treatments. It is expanding market share mainly in antibiotics, cancer pain relief drugs, and dyslipidemia treatments, with advanced technological development driving performance recovery. The company is actively promoting sustainability initiatives and organizational restructuring, including business succession to subsidiaries such as Shionogi Healthcare. Focusing on new drug development in the infectious disease area to address global antimicrobial resistance issues, it positions global expansion of infectious disease drugs and high-value-added pharmaceuticals as strategic pillars going forward. Recently, it plans to relocate its head office to the Umekita area in northern Osaka in 2025 to improve organizational efficiency and promote innovation. It is strengthening partnerships and acquisitions, with a focus on vaccines and biopharmaceuticals. While wary of political regulatory risks and intensifying market competition, it is executing its growth strategy.

Trivia

Interesting Facts

  • Founded in 1878, one of Japan's oldest pharmaceutical companies.
  • Company emblem features a balance weight symbolizing 'accuracy' and 'trust.'
  • Top sales class in the industry during the antibiotic boom era.
  • Long-time sole sponsor of Fuji TV's 'Music Fair.'
  • Domestic sales of Ensitrelvir as an infectious disease treatment.
  • Developed world's first injectable neuraminidase inhibitor Rapiacta.
  • Established office to promote proper use of infectious disease drugs addressing antibiotic resistance.
  • Engages in education support and promotion of employment for people with disabilities beyond pharmaceuticals.
  • Founded in Dojima, central to Osaka's pharmaceutical industry, and head office still located there.
  • Group company with numerous pharmaceutical-related subsidiaries.
  • Maintains Crestor's brand value even after patent expiration.
  • Historical sponsor of F1 team Lotus.
  • First in pharmaceutical industry to promote strategic IT partnerships.
  • Acquired exclusive Japan sales rights for Isodine from Mundipharma.
  • Certified special subsidiary for disability employment in 2018.

Hidden Connections

  • Previously co-marketed Crestor with AstraZeneca but transitioned to sole sales in 2023.
  • Manufacturing and marketing partnership with Mundipharma, supplying opioid analgesics.
  • Long-term historical product introductions and drug discovery collaborations with Eli Lilly.
  • Partnership with Hitachi and its group companies for IT operations.
  • Owns Shionogi Healthcare, which has partial capital from Rohto Pharmaceutical.
  • First in Japan to approve and launch COVID-19 treatment drug.
  • Ongoing sponsor partner with multiple broadcasters including FM802 in Osaka and TV Tokyo.
  • Established joint venture with Accenture to strengthen IT strategic reforms.

Future Outlook

Growth Drivers

  • Expanding demand for new infectious disease treatments addressing antimicrobial resistance.
  • Market growth in cancer pain relief and dyslipidemia drugs.
  • Entry into digital health and strengthened IT utilization.
  • Advancement of R&D in biopharmaceuticals and peptide APIs.
  • Strengthened sales force domestically and abroad with accelerated global expansion.
  • Product development and regulatory compliance aligned with government pharmaceutical policies.
  • Investment in advanced automation of manufacturing and research facilities.
  • Enriched product portfolio through new product licensing acquisitions.
  • Improved social evaluation through sustainability promotion.
  • Synergy creation with subsidiaries and partner companies.

Strategic Goals

  • Strengthen competitiveness and expand share in global infectious disease drug market.
  • Increase R&D investment and create innovative pharmaceuticals.
  • Achieve group-wide sustainability goals.
  • Promote DX (digital transformation).
  • Strengthen revenue base through diverse business portfolio.
  • Proper supply of medical narcotics and new dosage form development.
  • Expand regional healthcare and social contribution activities.
  • Deepen strategic partnerships with global partners.
  • Promote introduction of technological innovations for environmental impact reduction.
  • Enhance quality control and risk management.

Business Segments

Pharmaceutical Contract Manufacturing

Overview
Provides contract manufacturing services for pharmaceuticals to achieve high-quality production.
Competitiveness
Long years of pharmaceutical technology and rigorous quality control system
Customers
  • Domestic pharmaceutical companies
  • Foreign pharmaceutical companies
  • Biotech ventures
  • Research institutions
Products
  • API manufacturing
  • Formulation processing
  • Quality testing
  • Clinical trial drug manufacturing

Drug Discovery Research Support Services

Overview
Provides comprehensive support for chemical synthesis and evaluation testing required for drug discovery research.
Competitiveness
Multifaceted research support and specialized expertise
Customers
  • Pharmaceutical companies
  • Biotechnology companies
  • University research institutes
Products
  • Synthetic chemistry
  • Pharmacological evaluation
  • Animal testing support
  • Biopharmaceutical development

Healthcare Solutions

Overview
Provides solutions and services related to health management and education.
Competitiveness
Medical knowledge and technical foundation as a pharmaceutical manufacturer
Customers
  • Medical institutions
  • Nursing homes
  • Educational institutions
  • Health-related companies
Products
  • Educational support
  • Health management systems
  • Training services
  • Digital health

Competitive Advantage

Strengths

  • Rich product portfolio in infectious diseases
  • High research and development capabilities and drug discovery technology
  • Strong sales force and domestic and international distribution networks
  • Abundant track record in antibiotics
  • Globally recognized dyslipidemia drug development capabilities
  • Diversified business expansion utilizing subsidiaries
  • Long history and established brand strength
  • Strong financial base and stable revenue
  • Multifaceted research support services
  • Social contribution through proper use of infectious disease drugs
  • Advanced manufacturing technology and quality control systems
  • Active corporate acquisitions and partnership strategies
  • Promotion of digital transformation

Competitive Advantages

  • Leading in Japan in infectious disease treatment development, spearheading antimicrobial resistance measures
  • Patents and technological strength of blockbuster drugs like Crestor
  • High trust in medical institutions through sales and academic collaboration
  • Revenue stability from diverse business portfolio
  • Broad contract orders and collaborations in pharmaceutical technology
  • Global expansion via overseas subsidiaries and joint ventures
  • Balancing sustainable pharmaceutical development with social contributions
  • Continuous R&D investment enabled by solid financial strength
  • Business efficiency improvement through introduction of latest digital technologies
  • Participation in cutting-edge research on special peptides and other advanced raw materials
  • Strategic product succession and licensing utilization
  • Market share backed by long track record
  • Stable sales network with diverse customer base

Threats

  • Risk of market shrinkage due to increasing antimicrobial resistance
  • Uncertainty in responding to mutations in novel viruses and other infectious diseases
  • Government regulation on drug prices and downward pressure on reimbursement prices
  • Decline in global market share due to intensifying international competition
  • Risk of delays in new drug development or clinical trial failures
  • Concerns over loss of revenue sources due to patent expirations
  • Rising development and sales costs from strengthened regulations
  • Intensifying competition with generic drugs
  • Impact on overseas expansion from political risks and trade friction
  • Impact on production facilities from natural disasters
  • Revenue fluctuation risk due to reliance on infectious disease drugs
  • Restrictions on sales activities from strengthened regulations on relationships with healthcare professionals

Innovations

2022: Emergency Approval for Infectious Disease Treatment Drug Ensitrelvir

Overview
Obtained approval as an oral treatment for COVID-19.
Impact
Captured market share as Japan's only oral COVID drug.

2023: Group Brand Mark Redesign

Overview
Logo refresh to improve visibility and strengthen modern brand strategy.
Impact
Enhanced brand image and increased recognition.

2021: Strategic IT Partnership with Hitachi

Overview
Began joint promotion of group IT operations and development.
Impact
Improved business efficiency and promoted digital transformation.

2020: Full Acquisition of UMN Pharma

Overview
Completed acquisition to strengthen biopharmaceutical R&D structure.
Impact
Expanded biopharmaceutical business and accelerated technology.

2023: Joint Venture with Accenture

Overview
Business rollout toward advanced IT and efficiency in group operations.
Impact
Cost reduction and enhanced competitiveness through IT optimization.

Sustainability

  • Supporting suppression of resistant bacteria through proper use promotion of infectious disease drugs
  • Established special subsidiary company to promote employment of people with disabilities
  • Efforts to reduce environmental impact in sustainable pharmaceutical processes
  • Business efficiency and digitalization through organizational restructuring
  • Enhanced CSR activities for coexistence with local communities